SCHEMBL6740070

SCHEMBL6740070

COc1ccc(-c2ccc(C)cc2)c(OC)c1C(=O)O

nearest known ligand 0.50

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KMT2A Q03164 2/20 0.50
MEN1 O00255 1/20 0.50
PRNP P04156 1/20 0.50
ATM Q13315 1/20 0.50
L3MBTL1 Q9Y468 1/20 0.50
CA12 O43570 1/20 0.47
CA1 P00915 1/20 0.47
CA2 P00918 1/20 0.47
CA7 P43166 1/20 0.47
CA9 Q16790 1/20 0.47
CA14 Q9ULX7 1/20 0.47
TUBB4A P04350 5/20 0.43
TUBB P07437 5/20 0.43
TUBA3C P0DPH7 5/20 0.43
TUBA1B P68363 5/20 0.43
TUBA4A P68366 5/20 0.43
TUBB4B P68371 5/20 0.43
TUBB3 Q13509 5/20 0.43
TUBB2A Q13885 5/20 0.43
TUBB8 Q3ZCM7 5/20 0.43

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL28188288 0.88 CA1 (0.49) CA12CA1CA2CA7CA9
SCHEMBL4063174 0.87 CA12 (0.55) KMT2AMEN1ATMCA12CA1
SCHEMBL3901924 0.79 CA12 (0.62) KMT2AMEN1PRNPATML3MBTL1
SCHEMBL4849364 0.77 CA12 (0.63) KMT2AMEN1ATML3MBTL1CA12
SCHEMBL28180336 0.77 CA12 (0.50) CA12CA1CA2CA7CA9
SCHEMBL30805788 0.76 CA12 (0.57) KMT2AMEN1L3MBTL1CA12CA1
SCHEMBL27303132 0.76 CA12 (0.57) KMT2AMEN1L3MBTL1CA12CA1
SCHEMBL27717648 0.76 HTT (0.51) KMT2AMEN1L3MBTL1CA12CA1
SCHEMBL4062444 0.75 KDM4E (0.46) KMT2AMEN1L3MBTL1CA12CA1
SCHEMBL2044179 0.74 CA1 (0.51) KMT2AMEN1CA12CA1CA2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20040043995-A1 Novel triazole derivatives, process for their preparation and pharmaceutical compositions containing them BIGNON ERIC (FR) 2004-03-04 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20040043995-A1 Novel triazole derivatives, process for their preparation and pharmaceutical compositions containing them CCKAR, CCKBR, NPY1R KMT2A 4045/4885MEN1 2842/4885PRNP 4624/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.